Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
Monopar Therapeutics (NASDAQ:MNPR) Shares Gap Down After Earnings Miss
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Rating of “Buy” by Analysts
Does Monopar Therapeutics (MNPR) Have the Potential to Rally 42.46% as Wall Street Analysts Expect?
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout
Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
3 Momentum Stocks Soaring Into 2025 and Beyond
What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing'
What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing'
Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?
Monopar Therapeutics Skyrockets 400% on Licensing Deal
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate